145 related articles for article (PubMed ID: 37870341)
1. [Heart failure secondary to amyloidosis AL: diagnosis and treatment].
Pérez Lloveras E; Decotto S; Villanueva E; Marco MA; Carretero M; Posadas-Martinez ML; Pérez De Arenaza D; Nucifora E; Aguirre MA
Medicina (B Aires); 2023; 83(5):811-815. PubMed ID: 37870341
[TBL] [Abstract][Full Text] [Related]
2. [Heart transplantation and the subsequent treatment of AL amyloidosis].
Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
[TBL] [Abstract][Full Text] [Related]
3. Light-chain cardiac amyloidosis: a case report of extraordinary sustained pathological response to cyclophosphamide, bortezomib, and dexamethasone combined therapy.
Porcari A; Pagura L; Rossi M; Porrazzo M; Dore F; Bussani R; Merlo M; Sinagra G
Eur Heart J Case Rep; 2022 Apr; 6(4):ytac130. PubMed ID: 35652085
[TBL] [Abstract][Full Text] [Related]
4. Total Artificial Heart Implantation as a Bridge to Heart Transplantation in an Active Duty Service Member With Amyloid Cardiomyopathy.
Scully MS; Wessman DE; McKee JM; Francisco GM; Nayak KR; Kobashigawa JA
Mil Med; 2017 Mar; 182(3):e1858-e1860. PubMed ID: 28290973
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.
Sperry BW; Ikram A; Hachamovitch R; Valent J; Vranian MN; Phelan D; Hanna M
J Am Coll Cardiol; 2016 Jun; 67(25):2941-8. PubMed ID: 27339491
[TBL] [Abstract][Full Text] [Related]
6. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.
Chen W; Ton VK; Dilsizian V
Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480
[TBL] [Abstract][Full Text] [Related]
7. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis.
Mancio Silva J; Fontes-Carvalho R; Valente D; Almeida C; Cruz AJ; Tente D; Coelho H; Oliveira M; Albuquerque A; Ribeiro VG
Am J Case Rep; 2015 Mar; 16():174-81. PubMed ID: 25803181
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
11. Strange case of biventricular heart failure.
Biolè C; Bianco M; Parente A; Montagna L
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33462057
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and clinical manifestations of cardiac amyloidosis.
Bajwa F; O'Connor R; Ananthasubramaniam K
Heart Fail Rev; 2022 Sep; 27(5):1471-1484. PubMed ID: 34694575
[TBL] [Abstract][Full Text] [Related]
13. Cardiac amyloidosis as a rare cause of heart failure: A case report.
Gao M; Liu Q; Chen L
Medicine (Baltimore); 2019 Apr; 98(14):e15036. PubMed ID: 30946343
[TBL] [Abstract][Full Text] [Related]
14. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
15. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
[TBL] [Abstract][Full Text] [Related]
16. [Treatment strategy for immunoglobulin light chain amyloidosis].
Fuchida SI
Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis.
Puig-Carrion GD; Reyentovich A; Katz SD
Clin Auton Res; 2019 Sep; 29(Suppl 1):45-53. PubMed ID: 31452023
[TBL] [Abstract][Full Text] [Related]
18. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
19. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of heart failure in transthyretin vs. light chain amyloidosis.
Binder C; Duca F; Stelzer PD; Nitsche C; Rettl R; Aschauer S; Kammerlander AA; Binder T; Agis H; Kain R; Hengstenberg C; Mascherbauer J; Bonderman D
Eur Heart J Cardiovasc Imaging; 2019 May; 20(5):512-524. PubMed ID: 30649240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
